ClinVar Miner

Submissions for variant NM_004304.5(ALK):c.3313A>G (p.Ile1105Val)

gnomAD frequency: 0.00001  dbSNP: rs1426033956
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000691079 SCV000818819 uncertain significance Neuroblastoma, susceptibility to, 3 2022-10-08 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). ClinVar contains an entry for this variant (Variation ID: 570258). This variant has not been reported in the literature in individuals affected with ALK-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1105 of the ALK protein (p.Ile1105Val).
Ambry Genetics RCV001019907 SCV001181321 uncertain significance Hereditary cancer-predisposing syndrome 2022-05-26 criteria provided, single submitter clinical testing The p.I1105V variant (also known as c.3313A>G), located in coding exon 20 of the ALK gene, results from an A to G substitution at nucleotide position 3313. The isoleucine at codon 1105 is replaced by valine, an amino acid with highly similar properties. This alteration has been observed in at least one individual with a personal history that is consistent with ALK-related neuroblastic tumor susceptibility-related disease (Ambry internal data). This amino acid position is not well conserved in available vertebrate species, and valine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
GeneDx RCV003322808 SCV004028324 uncertain significance not provided 2023-02-17 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Baylor Genetics RCV000691079 SCV004190402 uncertain significance Neuroblastoma, susceptibility to, 3 2023-06-28 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.